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Background: The management of patients with heart failure
is a daily challenge for cardiologists and cardiac surgeons.
Pharmacotherapy, atrio-biventricular resynchronization, my-
ocardial revascularization, valve repair techniques, latissimus
dorsi cardiomyoplasty, acorn cardiac support device, heart
transplantation and mechanical assist devices do not cover all
Behandlung der Herzinsuffizienz mit autologen Skelettmyoblasten
Hintergrund: Die Behandlung der Herzinsuffizienz stellt trotz
Pharmakotherapie, biventrikulärer Resynchronisation, inter-
ventioneller und kardiochirurgischer Revaskularisation, der
Latissimus-doris-Kardiomyoplastie, der kardialen Assist-Sys-
teme und der Herztransplantation unverändert eine thera-
peutische Herausforderung an Kardiologen und Herzchirur-
gen dar. Neue molekularbiologische Techniken sind die Vor-
aussetzung für innovative Therapieansätze. Zu ihnen gehört
die autologe Myoblastentransplantation von ex vivo expan-
dierten Skelettmuskelzellen ins Myokard zur Herzmuskelrege-
neration.
Autologe Myoblastentransplantation: Vor den von der Ar-
beitsgruppe an der Universität Paris (Klinik Broussais) durch-
geführten ersten drei Transplantationen von Skelettmuskel-
myoblasten beim Menschen wurden u.a. Erfahrungen am 
Kardiotoxinmodell des Schafs vor und nach Myoblastentrans-
plantation mittels Kolorkinesis-Echokardiograpie (Abbildung
4) gesammelt. Die herzkatheterbasierte Applikation von Myo-
blasten wurde am gleichen Modell unter Verwendung des No-
ga-Systems (Abbildung 5) zum elektroanatomischen „Map-
ping“ erfolgreich erprobt und die Verbesserung der regionalen
Wandbewegung durch biventrikuläre Stimulation gezeigt. Ei-
ne De-novo-Angiogenese zeigte sich nur nach Vorbehandlung
der Tiere mit VGEF. Der Erfolg einer Myoblastentransplantati-
on hängt von der Zahl überlebender injizierter Myoblasten ab.
Dies ist in der Randzone eines Infarkts oder bei experimentel-
ler „Pacing-induzierter“ dilatativer Kardiomyopathie besser
als im Bereich einer Narbe. Bei den bisher drei am Menschen
vorgenommenen autologen Transplantation von Skelettmus-
kelmyoblasten konnte eine Reduktion der Infarktgröße er-
reicht werden. Die Expansion der Myoblasten im autologen
Serum ist dabei zur Vermeidung von immunologischen Ab-
wehrmechanismen, die unter bovinem Serumalbumin als
Nährmedium gezeigt wurden, von besonderer Bedeutung.
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the needs. The recent progress in cellular and molecular biolo-
gy allows the development of new therapies for heart failure. 
Transplantation of Autologous Cells: One of the most innova-
tive consists in the transplantation of autologous ex-vivo ex-
panded cells into the myocardium for heart muscle regenera-
tion. This approach is called “cellular cardiomyoplasty”. 
Schlüsselwörter: Zelluläre Kardiomyoplastik · Zellbiologie · Myoblasten · Zelltransplantation · Herzinfarkt ·
Herzinsuffizienz
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Introduction
Cellular cardiomyoplasty (CMP) consists of cell im-
plantation intended to induce the growth of new muscle
fibers and the development of angiogenesis in the dam-
aged myocardium that potentially may contribute to the
contractile performance of the heart [1]. Adult my-
ocardium cannot effectively repair after infarction due
to the limited number of stem cells [2]. Thus, most of the
injury is irreversible. For this reason, cell transplanta-
tion strategies for heart failure have been designed to
replace damaged cells with cells that can perform car-
diac work, either in ischemic or idiopathic cardiomy-
opathies [3].
Tissue regeneration techniques based on cell trans-
plantation technology have been previously used with
excellent long-term results for treatment of hemo-
pathies (chronic lymphocytic leukemia, aplastic anemia,
immunodeficiencies, myeloma). Cell-based therapy is
in development for other pathologies as neurodegener-
ative diseases (Huntington and Parkinson diseases,
spinal cord regeneration), hepatology (implantation of
hepatocytes as a bridge to liver transplantation), dia-
betes mellitus (transplantation of Langerhans islets),
myology (transplantation of myoblasts in Duchenne 
dystrophy), dermatology (implantation of cultured fi-
broblasts for dermal regeneration followed by kera-
tinocyte implantation for epidermal regeneration) and
in orthopedics (implantation of chondrocytes for repair
of articular defects of the knee). Interestingly, autolo-
gous cultured chondrocytes had been recently proposed
for lining the luminal surfaces of cardiovascular pros-
theses, in order to provide a strongly adherent artificial
surface [4].
Epidemiology
Ischemic myocardial disease, the main cause of heart
failure, is a major public health and economic problem.
Currently CABG is one of the most common major sur-
gical procedure in the United States and Western Eu-
rope, with over 200,000 procedures performed each
year. When comparing changes in quality of life of pa-
tients suffering from several chronic medical conditions,
heart failure patients consistently report the greatest
deterioration. Heart failure is a potentially lethal dis-
ease, the 5-year mortality rate is approximately 50%.
Among those with severe heart failure, the survival rate
at 3 years is only 25%. In view of the poor prognosis and
poor quality of life of patients with chronic heart failure,
it is appropriate that we review the role of new surgical
procedures in preventing recurrent heart failure. The
shortage of donors for heart transplantation compared
to the increase of numbers of potential recipients is the
most notorious problem for the terminal state of heart
failure [5, 6].
Cellular Cardiomyoplasty
Cellular cardiomyoplasty is a combination of cellular bi-
ology with cardiac surgery or with interventional cardi-
ology. Its aim is to regenerate the myocardium in order
to prolong and improve the quality of life of patients
who suffer from severe chronic cardiac deficiency and
who are unresponsive to medical treatment. In cellular
cardiomyoplasty, the cells of the same subject are used
to regenerate the myocardium which excludes the risk
of rejection and, therefore, no immunosuppressive
treatment is necessary [7–9].
Mechanisms of Beneficial Effects
The many proposed mechanisms of action of cellular
cardiomyoplasty are specified in Table 1.
Postischemic ventricular remodeling and diastolic
dysfunction are increasingly recognized as causes of
symptomatic heart failure. Conditions associated with
diastolic dysfunction are diverse and most commonly
include ischemic cardiomyopathy with previous my-
ocardial infarction(s) and hypertensive heart disease.
An underlying histopathologic finding is an adverse ac-
cumulation and structural remodeling of the heart’s fib-
rillar collagen matrix expressed as cardiac fibrosis [10].
Cell-based procedures should replace fibrosis by living
tissues, thus improving the rate of relaxation, diastolic
suction and passive stiffness [11].
Ventricular remodeling:
Reduces the size and fibrosis of infarct scars
Minimizes global ventricular dilatation
Increases myocardial wall thickness
Avoids postischemic remodeling
Diastolic function:
Improves myocardial wall tension and elasticity
Improves strain and dynamic stiffness
Reverses diastolic creep
Systolic function:
Improves regional ventricular wall motion
Increases developed pressures
Improves global ventricular contraction?
Table 1. Cellular cardiomyoplasty: Mechanisms of beneficial effects.
Tabelle 1. Zelluläre Kardiomyoplastik: Mechanismen und positive 
Effekte.
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Cells for Myocardial Regeneration
Current possibilities in cell therapy for heart failure are
the transplantation into the damaged myocardium of
different cell types: autologous myoblasts (satellite cells
originated from skeletal muscle), bone marrow-derived
stem cells, peripheral blood-derived stem cells, smooth
muscle cells, angioblasts and endothelial cells.
The two most investigated cells for myocardial re-
pair are skeletal myoblasts and bone marrow stem cells.
The major drawback for myoblasts is that these cells do
not contract spontaneously. Electrostimulation was pro-
posed by our group to transform passive cell therapy in-
to “dynamic cellular support” [12]. Bone marrow stem
cells can undergo milieu-dependent differentiation:
When transplanted in normal myocardium they can be-
come cardiocytes, but when these cells are implanted in
a myocardial scar they may differentiate into fibro-
blasts, becoming a “scar within a scar”. Stem cells can be
experimentally cultured and induced to differentiate to
a myogenic phenotype with 5-azacytidine. Co-cultures
of cardiomyocytes with stem cells had been proposed
for cell pre-differentiation [13–15].
Indications
Ischemic Cardiomyopathy
Patients in NYHA FC 2 or 3, presenting impaired left
ventricular function (ejection fraction between 20% and
40%), left ventricular wall postischemic scars (akinetic
and metabolically non-viable) are candidates for cellular
cardiomyoplasty. Ventricular wall thickness at echocar-
diographic evaluation should be > 4 mm. Right ventricu-
lar infarction is also an indication for cellular cardiomy-
oplasty. Concomitantly, patients can present indications
for CABG in remote, viable and ischemic areas.
Idiopathic Dilated Cardiomyopathy
Non-ischemic cardiomyopathy is also a frequent cause
of congestive heart failure. Cell transplantation could
offer new hopes in this disease by restoring impaired
systolic and diastolic functions. Interestingly, the grafted
cells appear to better survive in the host myocardium
because myocardial irrigation in this pathology is not
significantly impaired [16].
Methods and Procedures in Cellular 
Cardiomyoplasty
Cell-based therapies for heart diseases were conceived
to reverse the damage dysfunctional myocardial tissue
into a living histological structure, capable of generating
improved systolic and diastolic ventricular pressures.
The cellular cardiomyoplasty procedure using my-
oblasts consists: a) in a surgical biopsy of 10–15 g of a
skeletal muscle (e.g., the thigh vastus lateralis muscle),
b) in-vitro expansion of cells during 2–3 weeks, and, c)
the implantation of these cells into the ventricular wall.
To perform a cellular cardiomyoplasty procedure
using autologous myoblasts the steps described in Table
2 must be followed.
Skeletal Muscle Biopsy
3 weeks before the cellular cardiomyoplasty procedure,
under local anesthesia using lidocaine (2%) injected in-
to and around the selected muscle, a biopsy sample of
the thigh vastus lateralis muscle is taken through a 5 cm
incision (Figure 1). A 2–3 cm3 skeletal muscle piece (15
g) is explanted under sterile conditions. Immediate frag-
mentation of the muscle with scissors is performed, then
it is introduced in complete culture medium or in PBS
(phosphate buffer solution) and kept at 4° C. The oper-
ative wound is closed. The procedure for cell isolation
1. Removal of fibrous and adipose tissue from muscle biopsy
2. Muscle mincing with scissors
3. Enzymatic (collagenase + trypsin) and mechanical digestion
4. Multiple centrifugations
5. Isolation of myoblasts, exclusion of fibroblasts
6. In-vitro myoblasts culture: incubation during 3 weeks in humidified
atmosphere, at 37° C, 5% CO2
7. Assessment of percent cell viability (trypan blue)
8. Assessment of percent myoblasts/fibroblasts (CD56 antibodies + flow
cytometry, desmin antibody)
9. Sterility tests: bacterial viral, fungal
10. Cell suspension in 0.5% human albumin for myocardial injection
Table 2. Cellular cardiomyoplasty procedure.
Tabelle 2. Zelluläre Kardiomyoplastik: Methodik.
Figure 1. Muscular biopsy from the thigh vastus lateralis.
Abbildung 1. Skelettmuskelbiopsie vom Musculus vastus lateralis.
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and culture should start as soon as possible, so as to
guarantee cell survival. However, samples can be car-
ried in an appropriate container at low temperature,
and then transported to the cellular biology laboratory.
Injection Medium
On the day of transplantation, cells are harvested and
washed in the injection medium (human albumin 0.5%
+ complete culture medium) and kept in ice before im-
plantation. A sample is performed to assess final my-
oblasts rate by flow cytometry test (percentage of my-
oblasts CD56-positive/desmin-positive cells (Figures 2a
and 2b). The cell concentration and viability are deter-
mined with trypan blue using a Malassez cytometer.
Sterility of cell culture is also assessed before implanta-
tion (Gram tests) (Table 3).
Cell Implantation Procedure
Cellular implantation can be performed through an epi-
cardial or an endovascular delivery approach. The epi-
cardial approach (Figure 3) can be performed either by
conventional surgical exposure or thoracoscopy. In the
surgical approach (classic or mini-thoraco/sternotomy)
the ischemic area is well exposed thus permitting
around ten injections of cells suspended in 0.5% human
albumin (diluted in culture medium) in and principally
around the infarction, with a 23–26 G  4 cm curved
needle (e.g., 25 G  40 mm retrobulbar ophthalmic nee-
Figures 2a and 2b. a) Cultured myoblasts (satellite cells) ready to be transplanted into the myocardium. b) Histological study showing
myotubes developed 6 months after myoblasts implantation in a myocardial infarct.
Abbildungen 2a und 2b. a) Myoblastenkulturen (Satellitenzellen) unmittelbar vor Transplantation ins Myokard. b) Histologischer Nachweis von
Myotubes 6 Monate nach Implantation von Myoblasten in ein Infarktgewebe.
a b
Impantation of > 200 million cells
Density of cells: 50–70 million cells per ml
Time to culture: approximately 21 days
Myoblast concentration of > 70% myoblasts
Cell shelf life at 2–8° C are 96 hours
Table 3. Myoblast implantation protocol.
Tabelle 3. Myoblastenimplantation. Protokoll.
Figure 3. Transepicardial injection of cells, using a 25 G  40 mm
retrobulbar ophthalmic needle.
Abbildung 3. Transepikardiale Zellinjektion mit einer 25 G  40 mm
retrobulären ophthalmischen Kanüle.
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dle). Recommended density of cells is between 50 and
70 million cells per ml. The cell injection procedure
should be performed slowly and carefully, taking ap-
proximately 15 minutes. Cells should be delivered when
the 4 cm needle is slowly removed from the myocardi-
um. To improve injectate retention, needle holds should
be compressed with a finger 1–2 minutes after every in-
jection, in order to avoid regurgitation of the cell solu-
tion (channel leakage).
Cell mortality after transplantation seems to be im-
portant when they are grafted into high-fibrotic is-
chemic scars, since there are a great limitation of oxygen
and nutrients supply to the chronic ischemic myocardi-
um. Our approach consists in performing the main cell
implantation in the periinfarct area (70% of cells), since
the residual irrigation and collateral myocardial revas-
cularization in this intermediate area allows a better
survival of the implanted cells. The remaining 30% of
cells are implanted in the central part of the scar. The ef-
fects of this cell implantation procedure will be the cen-
tripetal reduction of the infarct area. For idiopathic di-
lated cardiomyopathies, multiple cell injections be-
tween the coronary arteries should be performed in the
myocardium of both ventricles. The grafted cells should
survive better in the host myocardium because myocar-
dial irrigation in non ischemic cardiomyopathies is not
significantly impaired [16].
Laboratory Investigations at University of Paris
(Broussais Hospital)
1. Evaluation of Regional Myocardial Function after
Cellular Therapy in a Cardiotoxin Model
The aim of cell transplantation into pathologic my-
ocardium is to repair, replace or enhance the biological
function of the altered ventricle, restoring a functional
myocardial mass, and hence improving the contractile
performance of the heart. In this study a reproducible
method for the creation of a myocardial lesion was de-
veloped [9]. The functional benefit of cell implantation
was evaluated by two-dimensional echocardiography
for global contraction and color-kinesis echocardiogra-
phy (CK, Hewlett Packard Sonos 5500), which allows
the precise assessment of the regional contraction (Fig-
ure 4). 
Methods: A left ventricular intramyocardial injection
(3 mg/1.5 ml) of snake cardiotoxin (C 9759, Sigma
Chem.) was carried out on a sheep model to induce a
well-delineated transmural lesion. 3 weeks later, the le-
sion was assessed by echocardiography. Thereafter, au-
tologous skeletal muscle cells (myoblasts) or culture me-
dia (control) were injected into the lesion. 2 months after
cell implantation, the myocardial contraction was again
evaluated by echocardiography and the implanted cells
were analyzed by a fast myosin heavy chain antibody.
Results: The snake cardiotoxin produced a well-de-
lineated transmural lesion in all animals. Echocardio-
graphic studies showed a significant improvement in
global and regional left ventricular function (RFAC) in
cell-treated sheep. Histologic analyses demonstrated
satellite cell survival, principally at the periphery of the
lesions. 
Conclusions: Satellite cells implanted in a car-
diotoxin-induced myocardial lesion survived for a 2-
month period and were associated with a significant
functional improvement of both local and global con-
traction. Local cardiotoxin administration generated
transmural necrosis, with severe damage of cardiomy-
ocytes and interstitial tissues (myocardial matrix).
2. Catheter-Based Cell Implantation for Myocardial
Regeneration
We studied the possibility of endoventricular cell im-
plantation in an experimental model of myocardial in-
farction [17]. Cell implantation was performed using a
specific catheter (Noga Biosense, Cordis Inc) guided by
electroanatomical mapping (Figures 5a and 5b).
Methods: To evaluate potential cell damage during
the implantation process, we tested in vitro the injection
Figure 4. Color-kinesis echocardiography: assessment of regional
fraction area change (RFAC) in a myocardial infarction model. 
Abbildung 4. Kolorkinesis-Echokardiographie: Bestimmung der Än-
derung der regionalen Flächen der Wandbewegung in einem Infarkt-
modell.
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of the cell suspension through the catheter. Afterwards,
in seven sheep we created a myocardial infarction by lig-
ation of two coronary branches. From a muscle biopsy
myoblasts were isolated and spread in culture for 3
weeks up to 50 million cells. In two sheep methylen blue
was injected in the myocardial scars by the catheter. In
five sheep the cells were implanted using this endoven-
tricular approach. At 2 months, histological and im-
munohistological studies were performed.
Results: In-vitro studies of catheters showed a low
residual volume of 70 µl, with cell integrity being pre-
served. Methylen blue was detected in the infarcted ar-
eas. Viable myoblasts were detected in the myocardium
and scar using specific antibodies.
Conclusions: The Biosense system with electro-
mechanical mapping of the heart allows the precise
guidance of the catheter to the infarcted zone. Viable
cells were detected in the implantation sites. Periodical-
ly repeated cell implantation procedures could be per-
formed with this system.
3. Myocardial Electrostimulation after Cellular 
Cardiomyoplasty
The principles of electrophysiological conditioning of
muscle fibers were applied by our group in cellular car-
diomyoplasty since skeletal myofibers express pre-
dominantly fatigue-sensitive fast myosin, which is not
suitable for cardiac work. Atrial synchronized biven-
tricular pacing is indicated in heart failure patients to
correct conduction disorders associated with chronic
systolic and diastolic dysfunction. We explored the
possibility to electrostimulate the ventricles following
autologous skeletal myoblast implantation to create 
an active cellular cardiac support, since skeletal 
myoblasts are known not to contract spontaneously
[12].
Methods: 22 adult sheep were included. All animals
underwent myocardial infarction by ligation of two
coronary arteries (distal LAD and D2). After 3 weeks,
autologous cultured myoblasts were injected in the in-
farcted areas. Atrial synchronized biventricular pacing
(BIV) was performed using epicardial electrodes, with a
pulse amplitude of 5 V and a pulse width of 0.5 ms. Ven-
tricular electrostimulation includes depolarization of
the implanted cells.
Results: Echocardiographic studies performed at 2
months showed a significant improvement in ejection
fraction (47 ± 6 vs 36 ± 4%) and a limitation of left ven-
tricular dilatation (49 ± 7 vs 69 ± 2 ml) in cell treated
biventricular pacing vs control group. Viable cells were
identified in the infarcted areas. Differentiation of my-
oblasts into myotubes was significantly improved in the
group associating cell therapy with biventricular pacing,
immunocytological studies showed enhanced expres-
sion of slow myosin heavy chain (MHC).
Conclusions: Electrostimulation induced the syn-
chronous contraction of transplanted myoblasts, thus
improving ventricular function. Histochemical studies
after pacing demonstrated enhanced expression of slow
MHC which is better adapted at performing cardiac
work. Simultaneous cardiac resynchronization can also
be achieved with this approach in order to correct con-
duction defects.
4. Angiogenic Growth Factors vs Cellular Therapy
for Myocardial Infarction
Locally delivered angiogenic growth factors and cell im-
plantation have been proposed for patients presenting
myocardial infarcts without possibility of percutaneous
or surgical revascularization. The goal of this study was
Figures 5a and 5b. a) Percutaneous Noga biosense catheter, used to
deliver cells into the myocardium from the left ventricular chamber. b)
Electroanatomical mapping of the heart showing the left ventricular
myocardial infarction (red area in the apex) and four cell injection
points (black points).
Abbildungen 5a und 5b. a) Perkutaner Noga-Biosense-Katheter, der
für myokardiale Applikation der Myoblasten aus dem linken Ventrikel
verwendet wird. b) Elektroanatomisches Mapping des Herzens: Die
rote apexnahe Fläche zeigt das Infarktgebiet, die schwarzen Punkte
die vier Stellen der Myoblasteninjektion.
a
b
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to compare the effects of these techniques, in an experi-
mental model of myocardial infarct [18].
Methods: 27 female sheep, weighing 21–34 kg, were
divided into four groups: In Group I (control) a my-
ocardial infarction was created and 0,5 ml of culture
medium was injected in the myocardial scar. In Group II
a myocardial infarction was created and 100 µg of
VEGF (vascular endothelial growth factor) were inject-
ed at 3 weeks. In Group III satellite cell implantation
was carried out 3 weeks after infarction. In Group IV
cell were associated to VEGF and injected simultane-
ously into the scar.
Results: Three animals died intraoperatively. Serum
troponin rose to 45.6 ± 4.7 ng/ml at postinfarction day 2.
Echocardiography showed a significant limitation of
left ventricular dilatation in the cell group: 57 ± 5.5 ml
(control group: 74.4 ± 5 ml, VEGF group: 68 ± 1.6 ml),
color-kinesis echo showed improvement of regional
fraction area change (RFAC) only in the cell group,
from 3.6 ± 0.8 to 21 ± 1.5%, p < 0.05. The number of cap-
illaries increased significantly in the periinfarct area of
VEGF group: 1036 ± 175 (control group: 785 ± 131, cell
group: 830 ± 75). Myoblast implantation did not induce
angiogenesis and angiogenic growth factors did not im-
prove myocardial contractility and remodeling. Simul-
taneous delivery of VEGF and cells did not demon-
strate beneficial effects.
Conclusions: Our results showed that cell therapy
improves regional myocardial contractility and reverses
left ventricular chamber remodeling. Angiogenesis was
only demonstrated in animals treated with VEGF (not
with cells). Any functional benefit was demonstrated in
the group treated with growth factors. The association
of VEGF with cells did not show beneficial effects. It
can be concluded that growth factors should be deliv-
ered in myocardial infarction several days before cell
transplantation in order to improve local conditions for
cell survival (preconditioning).
5. Cellular Therapy for Dilated Cardiomyopathy
Dilated cardiomyopathy is the end-point of various
pathologies affecting the myocardium [5]. We created
an experimental model of dilated cardiomyopathy in-
duced by ventricular rapid pacing to study the effects of
cell therapy on non-ischemic heart failure.
Methods: Dilated cardiomyopathy was created in
twelve sheep by implantation of two epicardial unipolar
leads on the right ventricle and the insertion of a pulse
generator into a subcutaneous pocket. Baseline mea-
sures of left ventricular function were made. Ventricular
pacing was initiated at a rate of 180 bpm for 4 months,
plus 1 month at 200 bpm. All animals were treated with
60 mg of frusemide when heart failure symptoms ap-
peared. Skeletal myoblasts (300 million) or culture
medium (control) were transplanted after 2 weeks after
inactivation of the pacemaker. At 3 months, hemody-
namic studies (P-V loops), echocardiography (tissue
Doppler), planimetry and histologic studies were per-
formed.
Preliminary Results: Rapid ventricular pacing pro-
duced a dilated cardiomyopathy that was still present 2
weeks after the PM inactivation, but with a spontaneous
tendency to reverse. Pressure/volume analysis showed a
ventricular overload and ventricular relaxation dys-
function. Tissue velocity imaging (ultrasound tech-
nique) was used to provide quantitative information
about regional systolic and diastolic myocardial motion,
to assess the extension of ventricular injury and the de-
gree of recovery in sheep. The rate of survival of im-
planted cells in non-ischemic cardiomyopahy may be
better, since the myocardial irrigation is still preserved
in this pathology.
Clinical Experience
In an attempt to repair damaged heart muscle and to im-
prove cardiac function, we have transplanted patient’s
own skeletal muscle cells (autologous myoblasts) di-
rectly into infarcted left ventricular areas in five cases.
Patients: Procedures were performed in four male
and one female patients, mean age 63 years, in NYHA
functional class III, presenting impaired left ventricular
function (ejection fraction 28 ± 3%), left ventricular
posterior wall postischemic scars (akinetic and metabol-
ically non-viable), and indications for CABG in remote,
viable and ischemic areas. Procedures were approved by
institutional review boards, informed written consent
was obtained from each patient. 
Procedure: During an outpatient procedure under
local anesthesia, surgical biopsies of 12 ± 3 g of a skele-
tal muscle (the thigh vastus lateralis muscle), were per-
formed. In the cellular biology laboratory skeletal mus-
cle stem cells (myoblasts) were isolated and in vitro ex-
panded in 17 ± 4 days up to 300 ± 20 millions. Cells were
cultivated in a complete human medium, using the own
patient serum obtained from patient blood sample (one
case) and from patient plasmapheresis (five cases). To
obtain a pure myoblast culture, fibroblasts were pro-
gressively eliminated from the flasks using the pre-plat-
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ting technique. At the moment of implantation, the rate
of myoblasts was 82 ± 5% and the rate of viable cells 95
± 3%. Afterwards the cells diluted in human albumin
and culture medium were placed in a syringe ready to be
injected. During a surgical procedure, through sternoto-
my CABG was performed (1.7 grafts/patient). The mus-
cle cells were then injected through 6 ± 2 injection
points into the posterior wall of the left ventricle, into
and around the infarcted areas, using a 25 G  40 mm
retrobulbar ophthalmic needle. 
Preliminary Results: Patients had uneventful recov-
ery and were discharged from the ICU 2 days after
surgery. At a mean follow-up of 6 ± 2 months no cardiac
arrhythmias were recorded. Echocardiographic studies
showed improvement of regional myocardial motion
(from akinetic scars to hypokinetic ventricular wall), re-
gional fractional shortening improved from 9 ± 3% to 20
± 5% (p < 0.05). The infarct scars size appear to be sig-
nificantly reduced: from 21 ± 5 cm2 to 8 ± 3 cm2 (p <
0.05). Myocardial viability tests showed regenerating
nodes. Patients moved from heart failure class III to
class I.
Conclusions
Our clinical results contrast with observations reported
by other investigators using fetal bovine serum (FBS)
for cell culture and in which 40% of patients required
defibrillator implantation [19]. Using FBS results in a 3-
week contact and fixation of animal proteins in the cell
surface, representing an antigenic and inflammatory
substrate for immunological adverse events. Moreover,
the cells expanded with FBS must be strongly washed
before human implantation, resulting in cellular injury.
Importantly, the use of autologous human serum for cell
cultures does not carry any risk of prion, viral or
zoonoses contaminations. 
Obtaining serum from patient blood sample has the
limitation of the amount of blood that can be drawn
from the patient. However, the use of plasmapheresis
allows a significantly larger supply of serum to be ob-
tained as there is no loss of patient blood cells during the
procedure thus providing a remarkable benefit for the
patient and for ICU hemodynamic management.
The technical approach used to implant the cells
should influence on the efficacy of cellular cardiomy-
oplasty. Cell mortality after transplantation seems to be
important when they are grafted in the center of high-fi-
brotic ischemic scars, since there is a great limitation of
oxygen and nutrients supply to the chronic ischemic my-
ocardium. Implanting the cells mainly in the periinfarct
areas may improve the rate of surviving cells, thus the
size of the infarct scar undergoes a centripetal reduc-
tion. Cells should be injected by multiple points de-
pending of the size and the configuration of the myocar-
dial diseased area. New developed percutaneous en-
doventricular catheters can be used for cell delivery
instead of surgery [17, 20]. However, the precise local-
ization of the diseased myocardium to be treated by
cells is still a challenge. 
Future research programs should be oriented on
the preconditioning for predifferentiation of stem cells
before transplantation, the optimization of the rate of
surviving cells after myocardial implantation, and the
improvement of host myocardium-transplanted cell
interactions [21–24]. Ventricular electrostimulation
should play an important role in transforming a pas-
sive cell-based procedure to a “dynamic cellular sup-
port” [12]. 
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